Get the Stockscreener App
0.9944
0.34%
0.0034
After Hours:
.98
-0.0144
-1.45%
Phio Pharmaceuticals Corp stock is traded at $0.9944, with a volume of 131.72K.
It is up +0.34% in the last 24 hours and down -7.93% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
See More
Previous Close:
$0.991
Open:
$1
24h Volume:
131.72K
Relative Volume:
0.23
Market Cap:
$11.55M
Revenue:
-
Net Income/Loss:
$-10.93M
P/E Ratio:
-0.6916
EPS:
-1.4378
Net Cash Flow:
$-10.72M
1W Performance:
-3.46%
1M Performance:
-7.93%
6M Performance:
-21.08%
1Y Performance:
-57.86%
1-Day Range:
$0.971
$1.02
1-Week Range:
$0.971
$1.12
52-Week Range:
$0.8127
$4.1899
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
0.9944 | 11.73M | 0 | -10.93M | -10.72M | -1.4378 |
VRTX
Vertex Pharmaceuticals Inc
|
502.31 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
738.72 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
187.46 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
930.52 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.87 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
A director buys 10,000 shares of Phio Pharmaceuticals (PHIO) at $1.03 and $1.04 per share. - Stock Titan
Phio Pharmaceuticals CEO Robert J. Bitterman Awarded 400,000 Restricted Stock Units - kalkinemedia.com
Phio Pharmaceuticals Director Ronald Todd Plott Granted 17,000 Restricted Stock Units - kalkinemedia.com
Phio Pharmaceuticals CFO Lisa Cabott Carson Granted 108,000 Restricted Stock Units - kalkinemedia.com
A director’s grant at Phio Pharmaceuticals (PHIO) covers 17,000 shares that vest in a year. - Stock Titan
A CEO's stock award will vest after a year at Phio Pharmaceuticals (PHIO). - Stock Titan
Phio Pharmaceuticals Stockholders Endorse 2026 Annual Meeting Proposals Including Director Elections and Incentive Plan Expansion - kalkinemedia.com
Phio Pharmaceuticals Expands Equity Incentive Pool at Meeting - TipRanks
Director Patricia Bradford Buys 6,500 Shares of Phio Pharmaceuti - GuruFocus
At $1.0127 a share, a Phio Pharmaceuticals (PHIO) director bought 6,500 shares. - Stock Titan
Phio Pharmaceuticals to Present Clinical Development Update - openPR.com
Phio Pharmaceuticals (PHIO) Chairman, President & CEO Robert Bit - GuruFocus
Phio Pharmaceuticals to Present Clinical Development Update & Upc - natlawreview.com
A CEO buys Phio Pharmaceuticals (PHIO) shares at $1.0289 each; reported direct holdings total 364,871 shares. - Stock Titan
Phio Pharmaceuticals Corp. (PHIO) Stock Price, News, Quote & History - Yahoo! Finance Canada
A potential skin cancer treatment completed a clinical study. Phio will discuss next steps Sept. 30. - Stock Titan
Live Phio Pharmaceuticals Corp. (PHIO) Technical Analysis - Traders Union
Phio Pharmaceuticals Corp. Stock Price Prediction: Today, Tomorrow, Next Week (PHIO) - Traders Union
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Phio Pharmaceuticals Corp (NASDAQ: PHIO) Share Price, PHIO Stock News, PHIO Share Price & Updates - kalkine.com.au
Phio Pharmaceuticals (NASDAQ: PHIO) Director Patricia A. Bradford Acquires 12,000 Shares at $1.03 Each - Kalkine Media
Phio Pharmaceuticals (PHIO) director buys shares with no 10b5-1 plan reported - Stock Titan
Phio Pharmaceuticals (PHIO) CEO has 68,550 shares withheld for taxes - Stock Titan
Phio Announces Key Development Milestone for PH-762 with FDA - openPR.com
Phio Pharmaceuticals (PHIO) CFO’s 12,888-share tax move involves no market sale - Stock Titan
Phio Announces PH-762 Milestone with FDA Submission Supporting Clinical Development in Cutaneous Squamous Cell Carcinoma - EIN News
Form 8K Phio Pharmaceuticals Corp For: 14 September By Investing.com - Investing.com Nigeria
King of Prussia's Phio Pharmaceuticals Submits FDA Briefing Package to Advance Its Skin Cancer Gene-Silencing Therapy - BioBuzz
Phio Advances PH-762 Toward Phase 2b Skin Cancer Trial - TipRanks
Phio Pharmaceuticals submits FDA briefing for PH-762 study By Investing.com - Investing.com Nigeria
Phio Pharmaceuticals submits FDA briefing for PH-762 study - Investing.com
Plans for a skin-cancer study reach the FDA after Phio completes an early trial - Stock Titan
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - openPR.com
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma - Yahoo Finance
Phio Pharmaceuticals to present clinical updates on cancer treatment PH-762 at H.C. Wainwright conference - Pluang
A potential nonsurgical treatment for skin cancers will be discussed at an investor conference - Stock Titan
PHIO Q2 2026 Earnings: EPS of -$0.36 Slightly Beats Consensus as Company Remains Pre-RevenueCEO Earnings Statement - dars.gov.et
Phio Pharmaceuticals Corp (PHIOW) Key Financial Ratios – Valuation, Profitability & More - Value Research
PHIO Should I Buy - Intellectia AI
Phio Pharmaceuticals director Plott buys $17,100 in shares - Investing.com
Phio Pharmaceuticals director Plott buys $17,100 in shares By Investing.com - Investing.com Canada
Phio Pharmaceuticals (PHIO) director snaps up 15,000 shares - stocktitan.net
Price to sales forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Phio Pharmaceuticals (PHIO) Chairman Robert Bitterman Buys 10,00 - GuruFocus
Phio Pharmaceuticals (PHIO) CEO boosts holdings to 431,421 shares - Stock Titan
Price to earnings forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Price to earnings forward of Phio Pharmaceuticals Corp. – BOATS:PHIO - TradingView
Phio Pharmaceuticals Corp. SEC Filing (Aug 14, 2026) - Stock Titan
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Compound PH-894 Targeting BRD4 Protein - The National Law Review
Phio Pharmaceuticals receives U.S. patent allowance for PH-894 By Investing.com - Investing.com Nigeria
Phio Pharmaceuticals receives U.S. patent allowance for PH-894 - Investing.com
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phio Pharmaceuticals Corp Stock (PHIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Plott Ronald Todd | Director |
Sep 28 '26 |
Buy |
1.03 |
5,000 |
5,150 |
37,000 |
| BRADFORD PATRICIA A | Director |
Sep 24 '26 |
Buy |
1.01 |
6,500 |
6,583 |
64,151 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Sep 22 '26 |
Buy |
1.03 |
2,000 |
2,058 |
364,871 |
| BRADFORD PATRICIA A | Director |
Sep 15 '26 |
Buy |
1.03 |
12,000 |
12,360 |
57,651 |
| Plott Ronald Todd | Director |
Aug 19 '26 |
Buy |
1.14 |
15,000 |
17,100 |
15,000 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Aug 18 '26 |
Buy |
1.06 |
10,000 |
10,600 |
431,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Jun 26 '26 |
Buy |
0.99 |
10,000 |
9,900 |
421,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 31 '25 |
Buy |
1.03 |
5,000 |
5,150 |
291,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 23 '25 |
Buy |
1.02 |
5,000 |
5,100 |
286,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 21 '25 |
Buy |
1.14 |
5,000 |
5,700 |
281,421 |
1.96%
1.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):